Mitesh Borad, MD
Hematology & Oncology · Scottsdale, AZNPI 1801850573
Payments from drug & device makers
Across 617 payments — averaging $5796.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$866K
- Incyte Corporation$744K
- Astellas Pharma Global Development$359K
- EMD Serono, Inc.$296K
- Agios Pharmaceuticals, Inc.$270K
- Pfizer$178K
- plus $863K from 29 others
Across 9 payments — averaging $338.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
- EMD Serono, Inc.$1K
- Taiho Oncology, Inc.$26
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $866,130 |
| Incyte Corporation | 259 | $743,872 |
| Astellas Pharma Global Development | 6 | $358,870 |
| EMD Serono, Inc. | 74 | $296,343 |
| Agios Pharmaceuticals, Inc. | 52 | $270,090 |
| Pfizer | 13 | $178,177 |
| Eli Lilly | 4 | $163,341 |
| Sanofi US Services Inc. | 11 | $140,107 |
| Lexicon Pharmaceuticals, Inc. | 2 | $121,681 |
| Puma Biotechnology, Inc. | 17 | $92,462 |
| Astrazeneca UK Limited | 6 | $82,790 |
| Redhill Biopharma Inc. | 3 | $64,178 |
| Halozyme Inc | 72 | $61,728 |
| Tersera Therapeutics LLC | 5 | $30,750 |
| Astellas US Technologies | 3 | $27,870 |
| Novartis | 4 | $15,462 |
| Jazz Pharmaceuticals Inc. | 10 | $12,315 |
| Merck | 11 | $9,884 |
| Bristol Myers Squibb | 3 | $7,395 |
| Servier Bioinnovation | 3 | $5,680 |
| Modernatx, Inc. | 2 | $4,898 |
| Genentech USA, Inc. | 7 | $3,946 |
| Boehringer Ingelheim | 1 | $3,900 |
| LES Laboratoires Servier | 1 | $3,156 |
| Servier Pharmaceuticals LLC | 3 | $2,871 |
| Eisai Inc. | 5 | $2,791 |
| Daiichi Sankyo Inc. | 3 | $2,668 |
| Exelixis Inc. | 1 | $1,980 |
| Ipsen Biopharmaceuticals, Inc | 2 | $258 |
| Tempus AI, Inc | 2 | $209 |
| Astrazeneca AB | 2 | $188 |
| AVEO Pharmaceuticals, Inc. | 1 | $161 |
| Coherus Oncology, Inc. | 1 | $121 |
| Taiho Oncology, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$3,576,298 in reported general payments places this provider in the 90th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Scottsdale
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Daniel AhnScottsdale$9.1M
- Saurabh ChhabraScottsdale$6.5M
- Peter BergsagelScottsdale$3.6M
- Cassandra MooreScottsdale$3.5M
- Alexander StewartScottsdale$3.2M
- Christopher DisimoneScottsdale$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.